Skip to main content
NCBI home page
Journal of Interferon & Cytokine Research logoLink to Journal of Interferon & Cytokine Research
. 2023 Oct 9;43(10):478–486. doi: 10.1089/jir.2023.0066

DNA-Dependent Interferon Induction and Lung Inflammation in Bordetella pertussis Infection

Jeremy Ardanuy 1, Karen M Scanlon 1, Ciaran Skerry 1, Nicholas H Carbonetti 1,✉
PMCID: PMC10599430  PMID: 37651198

Abstract

Pertussis, caused by Bordetella pertussis, is a resurgent respiratory disease but the molecular mechanisms underlying pathogenesis are poorly understood. We recently showed the importance of type I and type III interferon (IFN) induction and signaling for the development of lung inflammation in B. pertussis-infected mouse models. Classically, these IFNs are induced by signaling through a variety of pattern recognition receptors (PRRs) on host cells. Here, we found that the PRR signaling adaptor molecules MyD88 and TRIF contribute to IFN induction and lung inflammatory pathology during B. pertussis infection. However, the PRRs Toll-like receptors (TLR) 3 and TLR4, which signal through TRIF and MyD88, respectively, played no role in IFN induction. Instead, the DNA-sensing PRRs, TLR9 and STING, were important for induction of type I/III IFN and promotion of inflammatory pathology, indicating that DNA is a major inducer of lung IFN responses in B. pertussis infection. These results increase our understanding of this host–pathogen interaction and identify potential targets for host-directed therapies to reduce B. pertussis-mediated pathology.

Keywords: type I interferon, type III interferon, pattern recognition receptors, Bordetella pertussis infection

Introduction

The recent resurgence in pertussis (whooping cough) is a major public health issue, with hospitalization and mortality in infants and severe prolonged disease in adults (Mattoo and Cherry, 2005). Infection of animal models with Bordetella pertussis, the causative agent of pertussis, results in prolonged inflammation of the airways (Pinto and Merkel, 2017; Scanlon et al., 2014; Zimmerman et al., 2018), but the host and pathogen factors that promote this inflammation are poorly understood.

Previously, we found that type I and type III interferons (IFNs) are induced in the lungs of B. pertussis-infected adult mice and exacerbate lung inflammatory pathology (Ardanuy et al., 2020). Type I IFNs signal through a heterodimeric receptor (IFNAR1/IFNAR2) and JAK/STAT pathways (Pestka et al., 2004). They are important cytokines for antiviral defense and are also involved in pathogenesis and inflammation in various disease models (McNab et al., 2015; Pestka et al., 2004). Type I IFNs also affect outcomes in bacterial infections, providing deleterious effects in some and protective effects in others (Gratz et al., 2011; Martin et al., 2009; Mayer-Barber et al., 2010; O'Connell et al., 2004; Plumlee et al., 2009). The more recently discovered type III IFNs (IFN-λ) induce a similar set of IFN-stimulated genes (ISGs) as type I IFNs (Lazear et al., 2019). IFN-λ signals through a JAK/STAT signaling pathway but utilizes a different heterodimeric receptor, IFNLR1/IL-10Rβ, expressed on epithelial cells and certain immune cells (Donnelly and Kotenko, 2010; Santer et al., 2020; Sommereyns et al., 2008).

Signaling through various pattern recognition receptors (PRRs) can induce type I/type III IFN in mammalian cells (Manes and Nita-Lazar, 2021). PRRs detect conserved microbial patterns, known as pathogen-associated molecular patterns (PAMPs), or host molecules released from damaged cells, known as damage-associated molecular patterns (Li and Wu, 2021). PRRs are located in the plasma membrane, endosomal membrane, or cytosol and include Toll-like receptors (TLRs), intracellular DNA sensors, such as cGAS/STING, and several others. Since B. pertussis is primarily an extracellular pathogen, surface and endosomal PRRs, such as TLR4, TLR7, and TLR9, are more likely to initiate IFN induction in response to infection than cytosolic PRRs (Higgins et al., 2003; Kawasaki and Kawai, 2014).

In contrast, multiple intracellular bacteria induce type I/III IFN in mammalian cells through nucleic acid or nucleotide sensors, including the AIM 2 inflammasome or the sensor/adaptor proteins cGAS/STING (Barker et al., 2013; Kim et al., 2017; Ori et al., 2017). Detection of unmethylated CpG bacterial DNA by TLR9 in endosomes is a major pathway for induction of type I IFN expression (Kumagai et al., 2008). In contrast, mammalian DNA has few unmethylated CpG sequences, although they are enriched in so-called “CpG islands,” particularly associated with gene promoters (Deaton and Bird, 2011), and self-DNA can be delivered to endosomes and trigger type I IFN production by complexing with antimicrobial peptides, such as LL37 or β-defensins (Lande et al., 2007; Tewary et al., 2013). In addition, mitochondrial DNA released by damaged or stressed host cells can bind and signal through cytosolic and endosomal PRRs (De Gaetano et al., 2021; Xu et al., 2022), another source of self-DNA that can contribute to IFN upregulation.

In this study, we aimed to identify the specific PRRs responsible for upregulation of type I/ type III IFN responses and associated lung inflammation in B. pertussis-infected mice. Our data indicate that these responses are dependent on TLR9 and STING and therefore that DNA is an important inducer of IFN responses in this infection.

Materials and Methods

Bacterial strain

A streptomycin-resistant derivative of B. pertussis Tohama was grown on Bordet–Gengou agar supplemented with 10% defibrinated sheep blood (Lampire, Pipersville, PA) and 200 mg/mL streptomycin at 37°C for 48 h.

Mouse infections

Mouse strains (C57BL/6, C57BL/6-129SF2/J, TRIF KO, TLR3 KO, TLR4 KO, TLR9 KO, STING KO, and MyD88 KO, all from Jackson Lab, Bar Harbor, ME) were used in accordance with an Institutional Animal Care and Use Committee protocol (University of Maryland, Baltimore, MD). Bacterial inocula were prepared in phosphate-buffered saline (PBS) and 2 × 106 colony forming units (CFU) were administered intranasally in 50 μL. C-176 STING antagonist (Med Chem Express, Monmouth Junction, NJ) was administered at 0, 2, 4 days postinoculation (dpi) intraperitoneally at 13 mg/kg per mouse. TLR9 antagonist ODN 2088 (Invivogen, San Diego, CA) was administered at 0, 2, 4 dpi at 2.5 mg/kg intraperitoneally. Following euthanasia, lungs were removed for analysis of bacterial burden, transcript levels, and inflammatory histopathology. In general, groups of mice consisted of four to six animals of both sexes. All experiments were repeated at least once.

RNA isolation and quantitative real-time reverse transcription-polymerase chain reaction

Lung tissue was flash-frozen, and RNA extraction was achieved using the RNeasy Microarray Tissue Kit (QIAGEN, Germantown, MD) following manufacturer's instructions and DNase-treated to remove DNA contamination. cDNA was synthesized using a reverse transcription system (Promega, Madison, WI) following manufacturer's instructions. Quantitative real-time polymerase chain reaction (PCR) was performed with SYBR Green/ROX Master Mix in a 7500 Fast Real-Time PCR system (Applied Biosystems, Waltham, MA). Hypoxanthine phosphoribosyltransferase (hprt) was used as a housekeeping control gene. PCR primers are listed in Supplementary Table S1. Expression was determined by calculating fold changes versus PBS-inoculated animals using the 2-ΔΔCT method.

Inflammatory pathology

Lungs were perfused with PBS, transferred to 10% buffered formalin and hematoxylin and eosin stained at the University of Maryland School of Medicine Pathology Laboratory. Histopathological findings were scored by multiple blinded investigators on a scale of 0–9 as described previously (Scanlon et al., 2014).

Statistical analysis

Data were analyzed using GraphPad Prism software. Student's t-test was used for determining significance between two groups, and two-way analysis of variance was used for determining significance between multiple groups.

Results

Type I/ type III IFN upregulation in B. pertussis-infected mice is MyD88- and TRIF-dependent

MyD88 is a crucial adaptor of numerous TLR signaling pathways, except for the TLR3/4 endosomal pathways that utilize the TRIF adaptor (Kawasaki and Kawai, 2014). B. pertussis infection with our standard dose (2 × 106 CFU) resulted in the death of all MyD88 KO mice by 7 dpi (data not shown). Using a lower dose of B. pertussis (5 × 105 CFU), the bacterial lung burden of MyD88 KO and C57BL/6 (WT) mice at 5 dpi showed no significant difference (Fig. 1A), but induction of lung type I/type III IFN expression was significantly lower in MyD88 KO mice (Fig. 1B), indicating that one or more TLR pathways utilizing the MyD88 adaptor are involved in IFN induction.

FIG. 1.

FIG. 1.

Open in a new tab

MyD88 KO and TRIF KO mice have reduced levels of induction of type I/type III IFNs in response to Bordetella pertussis infection. (A, B) MyD88 KO and WT C57BL/6 mice (n = 4–6) were infected, lungs were dissected at 5 dpi, and (A) CFU levels were quantified, and (B) IFNα, IFNβ, and IFNλ gene expression levels were measured by qRT-PCR. (C–E) TRIF KO and WT C57BL/6 mice (n = 7–8) were infected, lungs were dissected at 7 dpi, and (C) CFU levels were quantified, (D) H&E staining of lungs was performed to determine lung inflammatory pathology levels, and (E) IFNα, IFNβ, and IFNλ gene expression levels were measured by qRT-PCR. P-values are shown for statistical comparisons (ns, not significant, *P < 0.05, **P < 0.01). CFU, colony forming units; dpi, days postinoculation; H&E, hematoxylin and eosin; IFN, interferon; qRT-PCR, quantitative reverse transcription-polymerase chain reaction.

The TRIF signaling adaptor is required for both TLR3 and endosomal TLR4 signaling, as well as some cGAS/STING signaling pathways (Wang et al., 2017; Yamamoto et al., 2003). At 7 dpi, lung bacterial burdens in TRIF KO mice showed no significant difference from those in infected WT mice (Fig. 1C). However, lung inflammatory pathology scores and upregulation of type I/III IFN expression levels were significantly lower in TRIF KO mice (Fig. 1D, E), indicating that TRIF is also required for robust IFN upregulation in B. pertussis-infected mice. Induction of proinflammatory cytokine gene expression was also significantly reduced in infected TRIF KO mice (Supplementary Fig. S1A). These data narrow the potential PRRs involved in type I/type III IFN induction to several candidates, including TLR3, TLR4, TLR9, and cGAS-STING.

TLR9 and STING signaling contribute to IFN induction and lung inflammatory pathology during B. pertussis infection

TLR4 senses bacterial LPS and signals from endosomes through TRIF to induce IFN expression (Kawasaki and Kawai, 2014). Despite significantly increased lung bacterial loads in TLR4 KO mice compared to WT mice, lung proinflammatory cytokine induction and inflammatory pathology were lower but no significant differences in induction of IFNs were observed (Fig. 2A–C, Supplementary Fig. S1B). Therefore, TLR4 controls bacterial growth and contributes to lung inflammatory pathology but is not involved in induction of type I/type III IFNs in B. pertussis infection. TLR3 recognizes double-stranded RNA (Kawasaki and Kawai, 2014). B. pertussis-infected TLR3 KO mice showed no significant differences in bacterial loads, lung inflammatory pathology, or IFN expression levels from WT (C57BL/6-129SF2/J) mice (Fig. 2D–F), demonstrating that TLR3 is not involved in these outcomes.

FIG. 2.

FIG. 2.

Open in a new tab

TLR3 and TLR4 do not play a role in induction of type I/type III IFN in response to B. pertussis infection. TLR3 KO, TLR4 KO, C57BL/6 (WT controls for TLR4 KO), or C57BL/6–129SF2/J (WT controls for TLR3 KO) mice (n = 4–5) were infected and euthanized 7 dpi. Lungs were dissected and (A, D) CFU levels were quantified, (B, E) H&E staining of lungs was performed to determine lung inflammatory pathology levels, and (C, F) IFNα, IFNβ, and IFNλ expression levels were measured by qRT-PCR. P-values are shown for statistical comparisons (ns, not significant, *P < 0.05, ***P < 0.001).

Signaling through TLR9 is commonly associated with IFN induction (Ank et al., 2008; Kader et al., 2013; Ma et al., 2015; Mortezagholi et al., 2017; Parker and Prince, 2012). B. pertussis-infected TLR9 KO mice showed no significant difference in lung bacterial burden but had significantly lower lung inflammatory pathology scores and type I and type III IFN expression levels at 7 dpi compared to that in WT mice (Fig. 3A–C). Induction of proinflammatory gene expression was also lower in TLR9 KO mice (Supplementary Fig. S1C). In addition, infected WT mice treated with a TLR9 antagonist (ODN 2088) at 0, 2, and 4 dpi had equivalent bacterial loads, but a similar reduction in lung inflammatory pathology and IFN induction at 7 dpi (Fig. 3D–F). These data indicate that TLR9 signaling is involved in type I/type III IFN induction and promotion of lung inflammation but is not required for controlling B. pertussis infection.

FIG. 3.

FIG. 3.

Open in a new tab

TLR9 plays a significant role in induction of type I/III IFN in response to B. pertussis infection. (A–C) TLR9 KO and WT C57BL/6 mice (n = 8) were infected with B. pertussis and euthanized 7 dpi. Lungs were dissected, and (A) CFU levels were quantified, (B) H&E staining of lungs was performed to determine lung inflammatory pathology levels, and (C) IFNα, IFNβ, and IFNλ expression levels were measured by qRT-PCR. (D–F) WT C57BL/6 mice were infected with B. pertussis, TLR9 antagonist ODN 2088 or vehicle (n = 4) was administered intraperitoneally at 0, 2, and 4 dpi, and mice were euthanized 7 dpi. Lungs were dissected, and (D) CFU levels were quantified, (E) H&E staining of lungs was performed to determine lung inflammatory pathology levels, and (F) IFNα, IFNβ, and IFNλ expression levels were measured by qRT-PCR. P-values are shown for statistical comparisons (ns, not significant, *P < 0.05, **P < 0.01).

Another PRR potentially involved in IFN induction is the cGAS/STING cytosolic DNA sensor (Cai et al., 2014; Marinho et al., 2017). Although B. pertussis is considered primarily an extracellular pathogen, PAMPs from phagosomal bacteria can be translocated to the cytosol and signal through STING and other cytosolic PRRs (Ragland and Kagan, 2021). B. pertussis-infected STING KO mice showed no significant difference from WT mice in lung bacterial burdens but had significantly lower levels of lung inflammatory pathology, IFN expression levels, and induction of proinflammatory genes (Fig. 4A–C, Supplementary Fig. S1D). WT-infected mice treated with the selective STING antagonist C-176 (Haag et al., 2018) also had lower lung inflammatory pathology and induction of IFNβ, but not of the other IFNs, compared to control mice (Fig. 4D–F). These data demonstrate that both TLR9 and STING are important PRRs for induction of type I/type III IFN responses to B. pertussis infection therefore that DNA is a major inducer of these responses.

FIG. 4.

FIG. 4.

Open in a new tab

STING KO mice have reduced levels of lung inflammatory pathology and induction of type I/type III IFN in response to B. pertussis infection. (A–C) STING KO and WT C57BL/6 mice (n = 6–8) were infected with B. pertussis and euthanized 7 dpi. Lungs were dissected, and (A) CFU levels were quantified, (B) H&E staining of lungs was performed to determine lung inflammatory pathology levels, and (C) IFNα, IFNβ, and IFNλ expression levels were measured by qRT-PCR. (D–F) WT C57BL/6 mice were infected with B. pertussis, STING antagonist C-176 or vehicle (n = 4) was administered intraperitoneally at 0, 2, and 4 dpi, and mice were euthanized 7 dpi. Lungs were dissected, and (D) CFU levels were quantified, (E) H&E staining of lungs was performed to determine lung inflammatory pathology levels, and (F) IFNα, IFNβ, and IFNλ expression levels were measured by qRT-PCR. P-values are shown for statistical comparisons (ns, not significant, *P < 0.05, **P < 0.01).

Discussion

B. pertussis infection induces significant lung inflammation in animal models, and we previously showed the involvement of type I/type III IFNs in this inflammation in mice (Ardanuy et al., 2020). Here we found that the signaling adaptor molecules MyD88 and TRIF and the DNA-sensing PRRs TLR9 and STING are involved in the induction of type I/type III IFNs and lung inflammatory pathology during infection, whereas TLR3 and TLR4, other non-DNA binding PRRs dependent on TRIF or MyD88, are not involved.

We previously found that increased expression of TREM-1, a receptor associated with inflammatory response amplification (Bosco et al., 2016), is TLR9-dependent in B. pertussis-infected WT mice (Gallop et al., 2021), but otherwise there are no previous reports of the involvement of TLR9 or STING in B. pertussis infection, although TLR9 and STING agonists added to acellular pertussis vaccine were found to enhance bacterial control in mouse models (Allen et al., 2018; Auderset et al., 2019). However, TLR9 and STING induce type I IFN responses and affect bacterial loads in other infections (Koppe et al., 2012; Parker and Prince, 2012; Parker et al., 2011).

Our results indicate that DNA is the major inducer of type I/type III IFNs during B. pertussis infection, although the source of the DNA is unclear. While killed B. pertussis or biofilm growth are potential bacterial sources (Bosch et al., 2006), host cells represent another potential source. Typically, self-DNA released following cell death is degraded by macrophages (Kawane et al., 2014) but can also be delivered to the endosome and stimulate production of type I IFNs by complexing with antimicrobial peptides such as LL37 and β-defensins (Lande et al., 2007; Tewary et al., 2013). Since infection with B. pertussis induces upregulation of antimicrobial peptides in the airways (Elahi et al., 2006), self-DNA is a potential stimulator of IFN responses and lung inflammation. TLR9 responses to self-DNA have been observed in autoimmune diseases such as systemic lupus erythematosus (Arneth, 2019) as well as in infections where large numbers of cells are killed (Stanbery et al., 2020; Tian et al., 2007).

In addition, mitochondrial DNA released by damaged host cells can signal through cytosolic and endosomal PRRs (De Gaetano et al., 2021). Neutrophil extracellular traps (Conceicao-Silva et al., 2021) represent yet another source of IFN-inducing host DNA. However, we found that antibody-mediated depletion of neutrophils had no effect on lung IFN induction or inflammation in B. pertussis-infected mice (Ardanuy and Carbonetti, unpublished data). If self-DNA is the predominant inducer of type I/type III IFN during B. pertussis infection, it is presumably derived from damaged cells and tissues in the early phase of inflammation, which is independent of type I/type III IFNs [since they are not induced until several days into the infection (Ardanuy et al., 2020)] and dependent on other PRRs such as TLR4. We previously found that induction of lung proinflammatory cytokines in B. pertussis-infected mice occurs earlier than type I/type III IFN induction (Andreasen et al., 2009; Ardanuy et al., 2020).

DNA-mediated induction of IFNs and stimulation of increased inflammation would therefore represent a positive feedback effect that may account for some of the deleterious respiratory effects in pertussis. Although certain aspects of the inflammatory response would contribute to control of bacterial infection, such as recruitment of immune cells that ultimately clear the infection, our results indicate that DNA-mediated induction of IFN responses does not affect bacterial loads within the first week of infection, since TLR9 KO and STING KO mice show no differences in bacterial loads from WT mice.

In summary, our results demonstrate that the DNA-sensing PRRs TLR9 and STING are the major inducers of type I/type III IFN responses in the lungs of B. pertussis-infected mice. Since these IFN responses exacerbate lung inflammation, this indicates the potential for TLR9 or STING antagonist compounds as therapeutic options in pertussis infections, in conjunction with antibiotic treatment to clear the infection. DNase I treatment, as used in cystic fibrosis patients (Aitken, 1993), represents another therapeutic option, although this assumes that IFN-inducing DNA is present in the airways. It may be that individuals who are well into the paroxysmal stage of pertussis disease will receive little benefit from reducing inflammatory responses, but individuals postexposure in an outbreak situation with early symptoms may benefit from such treatment in combination with antibiotic therapy.

Supplementary Material

Supplemental data
Suppl_TableS1.docx (103.2KB, docx)
Supplemental data
Suppl_FigS1.docx (188.1KB, docx)

Acknowledgment

The authors thank Danisha Gallop for animal care and the Carbonetti laboratory members for helpful feedback on this project.

Author Disclosure Statement

No competing financial interests exist.

Funding Information

This work was supported by National Institutes of Health grants R01-AI141372 (to N.H.C.), F31-AI136377 (to J.A.), and T32-AI095190 (which supported J.A.).

Supplementary Material

Supplementary Figure S1

Supplementary Table S1

References

  1. Aitken ML. Clinical trials of recombinant human DNase in cystic fibrosis patients. Monaldi Arch Chest Dis 1993;48(6):653–656. [PubMed] [Google Scholar]
  2. Allen AC, Wilk MM, Misiak A, et al. Sustained protective immunity against Bordetella pertussis nasal colonization by intranasal immunization with a vaccine-adjuvant combination that induces IL-17-secreting T(RM) cells. Mucosal Immunol 2018;11(6):1763–1776; doi: 10.1038/s41385-018-0080-x [DOI] [PubMed] [Google Scholar]
  3. Andreasen C, Powell DA, Carbonetti NH. Pertussis toxin stimulates IL-17 production in response to Bordetella pertussis infection in mice. PLoS One 2009;4(9):e7079; doi: 10.1371/journal.pone.0007079 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Ank N, Iversen MB, Bartholdy C, et al. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol 2008;180(4):2474–2485; doi: 10.4049/jimmunol.180.4.2474 [DOI] [PubMed] [Google Scholar]
  5. Ardanuy J, Scanlon K, Skerry C, et al. Age-dependent effects of type I and type III IFNs in the pathogenesis of Bordetella pertussis infection and disease. J Immunol 2020;204(8):2192–2202; doi: 10.4049/jimmunol.1900912 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Arneth B. Systemic lupus erythematosus and DNA degradation and elimination defects. Front Immunol 2019;10:1697; doi: 10.3389/fimmu.2019.01697 [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Auderset F, Ballester M, Mastelic-Gavillet B, et al. Reactivating immunity primed by acellular pertussis vaccines in the absence of circulating antibodies: Enhanced bacterial control by TLR9 rather than TLR4 agonist-including formulation. Front Immunol 2019;10:1520; doi: 10.3389/fimmu.2019.01520 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Barker JR, Koestler BJ, Carpenter VK, et al. STING-dependent recognition of cyclic di-AMP mediates type I interferon responses during Chlamydia trachomatis infection. mBio 2013;4(3):e00018–00013; doi: 10.1128/mBio.00018-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Bosch A, Serra D, Prieto C, et al. Characterization of Bordetella pertussis growing as biofilm by chemical analysis and FT-IR spectroscopy. Appl Microbiol Biotechnol 2006;71(5):736–747; doi: 10.1007/s00253-005-0202-8 [DOI] [PubMed] [Google Scholar]
  10. Bosco MC, Raggi F, Varesio L. Therapeutic potential of targeting TREM-1 in inflammatory diseases and cancer. Curr Pharm Des 2016;22(41):6209–6233; doi: 10.2174/1381612822666160826110539 [DOI] [PubMed] [Google Scholar]
  11. Cai X, Chiu YH, Chen ZJ. The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. Mol Cell 2014;54(2):289–296; doi: 10.1016/j.molcel.2014.03.040 [DOI] [PubMed] [Google Scholar]
  12. Conceicao-Silva F, Reis CSM, De Luca PM, et al. The immune system throws its traps: Cells and their extracellular traps in disease and protection. Cells 2021;10(8); doi: 10.3390/cells10081891 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. De Gaetano A, Solodka K, Zanini G, et al. Molecular mechanisms of mtDNA-mediated inflammation. Cells 2021;10(11); doi: 10.3390/cells10112898 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev 2011;25(10):1010–1022; doi: 10.1101/gad.2037511 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Donnelly RP, Kotenko SV. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res 2010;30(8):555–564; doi: 10.1089/jir.2010.0078 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Elahi S, Buchanan RM, Attah-Poku S, et al. The host defense peptide beta-defensin 1 confers protection against Bordetella pertussis in newborn piglets. Infect Immun 2006;74(4):2338–2352; doi: 10.1128/IAI.74.4.2338-2352.2006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Gallop D, Scanlon K, Ardanuy J, et al. Triggering receptor expressed on myeloid cells-1 (TREM-1) contributes to Bordetella pertussis inflammatory pathology. Infect Immun 2021:IAI0012621; doi: 10.1128/IAI.00126-21 [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Gratz N, Hartweger H, Matt U, et al. Type I interferon production induced by Streptococcus pyogenes-derived nucleic acids is required for host protection. PLoS Pathog 2011;7(5):e1001345; doi: 10.1371/journal.ppat.1001345 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Haag SM, Gulen MF, Reymond L, et al. Targeting STING with covalent small-molecule inhibitors. Nature 2018;559(7713):269–273; doi: 10.1038/s41586-018-0287-8 [DOI] [PubMed] [Google Scholar]
  20. Higgins SC, Lavelle EC, McCann C, et al. Toll-like receptor 4-mediated innate IL-10 activates antigen-specific regulatory T cells and confers resistance to Bordetella pertussis by inhibiting inflammatory pathology. J Immunol 2003;171(6):3119–3127; doi: 10.4049/jimmunol.171.6.3119 [DOI] [PubMed] [Google Scholar]
  21. Kader M, Smith AP, Guiducci C, et al. Blocking TLR7- and TLR9-mediated IFN-alpha production by plasmacytoid dendritic cells does not diminish immune activation in early SIV infection. PLoS Pathog 2013;9(7):e1003530; doi: 10.1371/journal.ppat.1003530 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kawane K, Motani K, Nagata S. DNA degradation and its defects. Cold Spring Harb Perspect Biol 2014;6(6); doi: 10.1101/cshperspect.a016394 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kawasaki T, Kawai T. Toll-like receptor signaling pathways. Front Immunol 2014;5:461; doi: 10.3389/fimmu.2014.00461 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Kim JA, Park SK, Seo SW, et al. STING Is involved in antiviral immune response against VZV infection via the induction of type I and III IFN pathways. J Invest Dermatol 2017;137(10):2101–2109; doi: 10.1016/j.jid.2017.03.041 [DOI] [PubMed] [Google Scholar]
  25. Koppe U, Hogner K, Doehn JM, et al. Streptococcus pneumoniae stimulates a STING- and IFN regulatory factor 3-dependent type I IFN production in macrophages, which regulates RANTES production in macrophages, cocultured alveolar epithelial cells, and mouse lungs. J Immunol 2012;188(2):811–817; doi: 10.4049/jimmunol.1004143 [DOI] [PubMed] [Google Scholar]
  26. Kumagai Y, Takeuchi O, Akira S. TLR9 as a key receptor for the recognition of DNA. Adv Drug Deliv Rev 2008;60(7):795–804; doi: 10.1016/j.addr.2007.12.004 [DOI] [PubMed] [Google Scholar]
  27. Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007;449(7162):564–569; doi: 10.1038/nature06116 [DOI] [PubMed] [Google Scholar]
  28. Lazear HM, Schoggins JW, Diamond MS. Shared and distinct functions of Type I and Type III interferons. Immunity 2019;50(4):907–923; doi: 10.1016/j.immuni.2019.03.025 [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Li D, Wu M. Pattern recognition receptors in health and diseases. Signal Transduct Target Ther 2021;6(1):291; doi: 10.1038/s41392-021-00687-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Ma C, Spies NP, Gong T, et al. Involvement of DNA-PKcs in the type I IFN response to CpG-ODNs in conventional dendritic cells in TLR9-dependent or -independent manners. PLoS One 2015;10(3):e0121371; doi: 10.1371/journal.pone.0121371 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Manes NP, Nita-Lazar A.. Molecular mechanisms of the toll-like receptor, STING, MAVS, inflammasome, and interferon pathways. mSystems 2021:e0033621; doi: 10.1128/mSystems.00336-21 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Marinho FV, Benmerzoug S, Oliveira SC, et al. The emerging roles of STING in bacterial infections. Trends Microbiol 2017;25(11):906–918; doi: 10.1016/j.tim.2017.05.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Martin FJ, Gomez MI, Wetzel DM, et al. Staphylococcus aureus activates type I IFN signaling in mice and humans through the Xr repeated sequences of protein A. J Clin Invest 2009;119(7):1931–1939; doi: 10.1172/jci35879 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005;18(2):326–382; doi: 10.1128/CMR.18.2.326-382.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Mayer-Barber KD, Barber DL, Shenderov K, et al. Caspase-1 independent IL-1beta production is critical for host resistance to Mycobacterium tuberculosis and does not require TLR signaling in vivo. J Immunol 2010;184(7):3326–3330; doi: 10.4049/jimmunol.0904189 [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. McNab F, Mayer-Barber K, Sher A, et al. Type I interferons in infectious disease. Nat Rev Immunol 2015;15(2):87–103; doi: 10.1038/nri3787 [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Mortezagholi S, Babaloo Z, Rahimzadeh P, et al. Evaluation of TLR9 expression on PBMCs and CpG ODN-TLR9 ligation on IFN-alpha production in SLE patients. Immunopharmacol Immunotoxicol 2017;39(1):11–18; doi: 10.1080/08923973.2016.1263859 [DOI] [PubMed] [Google Scholar]
  38. O'Connell RM, Saha SK, Vaidya SA, et al. Type I interferon production enhances susceptibility to Listeria monocytogenes infection. J Exp Med 2004;200(4):437–445; doi: 10.1084/jem.20040712 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Ori D, Murase M, Kawai T. Cytosolic nucleic acid sensors and innate immune regulation. Int Rev Immunol 2017;36(2):74–88; doi: 10.1080/08830185.2017.1298749 [DOI] [PubMed] [Google Scholar]
  40. Parker D, Martin FJ, Soong G, et al. Streptococcus pneumoniae DNA initiates type I interferon signaling in the respiratory tract. mBio 2011;2(3):e00016–00011; doi: 10.1128/mBio.00016-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Parker D, Prince A. Staphylococcus aureus induces type I IFN signaling in dendritic cells via TLR9. J Immunol 2012;189(8):4040–4046; doi: 10.4049/jimmunol.1201055 [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004;202:8–32; doi: 10.1111/j.0105-2896.2004.00204.x [DOI] [PubMed] [Google Scholar]
  43. Pinto MV, Merkel TJ. Pertussis disease and transmission and host responses: Insights from the baboon model of pertussis. J Infect 2017;74 Suppl 1:S114–S119; doi: 10.1016/S0163-4453(17)30201-3 [DOI] [PubMed] [Google Scholar]
  44. Plumlee CR, Lee C, Beg AA, et al. Interferons direct an effective innate response to Legionella pneumophila infection. J Biol Chem 2009;284(44):30058–30066; doi: 10.1074/jbc.M109.018283 [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Ragland SA, Kagan JC. Cytosolic detection of phagosomal bacteria-Mechanisms underlying PAMP exodus from the phagosome into the cytosol. Mol Microbiol 2021;116(6):1420–1432; doi: 10.1111/mmi.14841 [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Santer DM, Minty GES, Golec DP, et al. Differential expression of interferon-lambda receptor 1 splice variants determines the magnitude of the antiviral response induced by interferon-lambda 3 in human immune cells. PLoS Pathog 2020;16(4):e1008515; doi: 10.1371/journal.ppat.1008515 [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Scanlon KM, Gau Y, Zhu J, et al. Epithelial anion transporter pendrin contributes to inflammatory lung pathology in mouse models of Bordetella pertussis infection. Infect Immun 2014;82(10):4212–4221; doi: 10.1128/IAI.02222-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Sommereyns C, Paul S, Staeheli P, et al. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008;4(3):e1000017; doi: 10.1371/journal.ppat.1000017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Stanbery AG, Newman ZR, Barton GM. Dysregulation of TLR9 in neonates leads to fatal inflammatory disease driven by IFN-gamma. Proc Natl Acad Sci U S A 2020;117(6):3074–3082; doi: 10.1073/pnas.1911579117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Tewary P, de la Rosa G, Sharma N, et al. beta-Defensin 2 and 3 promote the uptake of self or CpG DNA, enhance IFN-alpha production by human plasmacytoid dendritic cells, and promote inflammation. J Immunol 2013;191(2):865–874; doi: 10.4049/jimmunol.1201648 [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Tian J, Avalos AM, Mao SY, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007;8(5):487–496; doi: 10.1038/ni1457 [DOI] [PubMed] [Google Scholar]
  52. Wang X, Majumdar T, Kessler P, et al. STING requires the adaptor TRIF to trigger innate immune responses to microbial infection. Cell Host Microbe 2017;21(6):788; doi: 10.1016/j.chom.2017.05.007 [DOI] [PubMed] [Google Scholar]
  53. Xu L, Li M, Yang Y, et al. Salmonella induces the cGAS-STING-dependent type I interferon response in murine macrophages by triggering mtDNA release. mBio 2022;13(3):e0363221; doi: 10.1128/mbio.03632-21 [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Yamamoto M, Sato S, Hemmi H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003;301(5633):640–643; doi: 10.1126/science.1087262 [DOI] [PubMed] [Google Scholar]
  55. Zimmerman LI, Papin JF, Warfel J, et al. Histopathology of Bordetella pertussis in the baboon model. Infect Immun 2018;86(11); doi: 10.1128/IAI.00511-18 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental data
Suppl_TableS1.docx (103.2KB, docx)
Supplemental data
Suppl_FigS1.docx (188.1KB, docx)

Articles from Journal of Interferon & Cytokine Research are provided here courtesy of Mary Ann Liebert, Inc.

RESOURCES